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The fluoride numbers (FN) of 144 individuals referred to our laboratory for 
dibucaine number ( DN) determinations because of prolonged apnea following 
succinylcholine in the probands or relatives were determined by our new method 
using 2.5 × ]0 -4  M concentration of sodium fluoride at 37 C. Dibucaine-resistant 
homozygotes and heterozygotes both had lower FN than the normal homozy- 
gores. A linear correlation between DN and FN for all these genotypes was found 
which is described by the equation FN=O.59DN + 32. The correlation coeffi- 
cient was r = 0.94. This equation will help in the correct identification of atypical 
fluoride resistant geno types, since these ought to have an observed FN lower by 2 
standard deviations than the FN calculated from this equation. 
KEY WORDS: F N - D N  correlation: fluoride-resistant plasmacholinesterase, dibucaine-resistant 
plasmacholinesterase. 
INTRO DUCTIO N 
Genetic anomalies of the dibucaine-resistant (E}'E~), the fluoride-resistant 
(E~E~), and the silent (E~E)) homozygous plasmacholinesterase genotypes are 
known to be responsible for the prolonged paralysis of the respiratory muscles 
(prolonged apnea) and cardiac arrhythmias following the intravenous injec- 
tion of the usual 1.0 mg/kg dose of succinylcholine, the most widely used 
1 A preliminary report was presented at the American Society of Anesthesiologists' annual 
meeting, October 7-1 I, 1973. 
2 University of Michigan Medical Center, Ann Arbor, Michigan 48109. 
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muscle relaxant during anesthesia and surgery. The recognition of this ano- 
maly and the genetic survey of the index family after the identification of the 
proband may circumvent untoward reactions to succinylcholine in the 
affected relatives (Harris and Whittaker, 1961; Foldes et al., 1963). 
Since the discovery of the fluoride-resistant plasmacholinesterase, many 
cases of fluoride-resistant heterozygotes (E~F~ and only a few homozygotes 
(/~1~) have been reported (Harris and Whittaker, 1961; Whittaker, 1967, 
1968; Foldes et al., 1963; Whittaker and Vickers, 1970; Thompson and 
Whittaker, 1966). In all these studies Na fluoride at a concentration of 
5,0 x 10 -5 M was used, which was claimed to inhibit normal plasma cholines- 
terase to about 64% while the fluoride-resistant homozygote was inhibited to 
less than 34%. Some of the reports on fluoride-resistant genotypes lacked the 
determination of DN, although some reported dibucaine numbers were also 
found abnormal in the so-called fluoride-resistant homozygotes and fluoride- 
resistant-silent heterozygotes. Moreover, the determination of the fluoride 
number (FN) alone could not differentiate between fluoride-dibucaine-resis- 
tant heterozygotes and fluoride-resistant homozygotes. The latter could only 
be differentiated by a normal DN. 
The narrow range of percentages (64-34~o) of inhibition in the various 
genotypes with the use of 5.0 x 10 -5 M Na fluoride concentration at 25 C in 
contrast to the wide separation with the same concentration of dibucaine 
(15--75%) necessitated the development of a more specific method for the 
differentiation of the fluoride resistant phenotypes (Zsigmond, 1973). Because 
of the great dependence of the fluoride inhibition on temperature, we also 
increased the temperature from 25 to 37 C and increased the concentration of 
Na fluoride to 2.5 x 10 -4  M, which gives 75% inhibition in a normal homozy- 
gote. We have been utilizing this modified method during the past 5 years to 
determine whether the fluoride inhibition may also be dependent on dibucaine 
inhibition. Therefore, both DN and FN were determined in a large number of 
dibucaine-resistant genotypes (E~E~ and ETE~). 
MATERIALS AND METHODS 
Between 1973 and 1978 a total of 144 plasma samples of patients with a history 
of prolonged apnea following succinylcholine administration and their blood 
relatives were sent to our laboratory for the determination of DN and FN. 
The samples were stored at - 20 C until the time of determination. All the 
experiments were carried out at 37 C andpH 7.4. Benzoylcholine chloride at a 
concentration of  5.0 x 10 -5 M was used as a substrate for the determination of  
enzyme activity. Nupercaine hydrochloride at a concentration of 1.0 x 10 -5 M 
and Na fluoride at a concentration of 2,5 x 10 -4 M were used as inhibitors for 
the determination of DN and FN, respectively. All determinations were 
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carried out by a modification (Foldes et  al., 1960) of Kalow's ultraviolet 
spectrophotometric method using Beckman DU spectrophotometer at the 
wavelength of 240 nm. 
RESULTS AND DISCUSSION 
As shown in Table I, 50 individuals were normal homozygotes with mean + sD 
DN of 76.0_+2.7 and FN=77.0+3.2. Fifty-four individuals were atypical 
normal heterozygotes with mean + sI) DN of 59.0_+ 7.4 and FN = 67.0 + 5.4. 
The remaining 40 individuals were atypical dibucaine-resistant homozygotes 
with means + SD DN of 18.0 _+ 7.7 and FN = 43.0 + 10.0. It is evident that the 
dibucaine-resistant heterozygotes and homozygotes also have abnormal 
fluoride inhibition or FN. There is a linear correlation between DN and FN 
with the equation shown in Fig. 1 (r = 0.94). So far we have not observed any 
plasma sample where FN would be 2 sD lower than DN. Consequently we 
were unable to identify any fluoride resistant heterozygote or homozygote, 
while we observed the expected incidence of dibucaine-resistant silent and 
usual genotypes in a surgical and anesthetized patient population (Whittaker 
and Vickers, 1970). 
The original reports on the fluoride-resistant genotypes indicated a corre- 
lation between this genotype and prolonged apnea following succinylcholine 
administration (Harris and Whittaker, 1961; Whittaker, 1967; Whittaker and 
Vickers, 1970). Because of the paucity of the reported fluoride-resistant 
homozygotes with adequately documented prolonged apnea (Whittaker and 
Table I. Correlation of DN with FN in Apneic 
Patients and Relatives With Various Plasma- 
cholinesterase Genotypes 
BeCh 
Genotype HR  a DN FN 
E~E~ 86.62 76,0_+2.68 77.0_+3.22 
N = 5 0  +30.06 ~ _+0.38 +0.45 
_+4.25 c 
E~E~ 55.99 59,0_+7.41 67.0-+5.37 
N=54 _+23.59 -+ 1.00 _+0.73 
-+3.21 
E~E~ 29.80 18.0±7.66 43.0-+ 10.05 




b Standard deviation. 
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Fig. 1. Correlation of FN with Dn in various 
dibucaine-resistant genotypes. Note that the 
FN correlates linearly with the DN in all geno- 
types with a correlation coefficient of r =  0.94. 
This equation can be utilized to predict the 
expected Fn in a dibucaine-resistant genotype. 
The observed FN should be lower by 2 so 
deviation in a fluoride-resistant genotype than 
the value predicted from this equation. 
Vickers, 1970) and because of the occurrence of prolonged apnea even in a 
large number ofE~E~ (Foldes et al., 1963; Zsigmond et al., 1973), it is difficult 
to tell the clinical importance of fluoride-resistant genotypes. The only objec- 
tive scientific way to establish a correlation between the abnormal genotype 
and prolonged neuromuscular block induced by succinylcholine is to 
determine the duration of neuromuscular block in patients with the fluoride- 
resistant PChE following intravenous succinycholine infusion. 
CONCLUSION 
The reported correlation equation will, it is hoped, facilitate the correct 
identification of the fluoride-resistant genotypes of PChE, thereby avoiding 
erroneous reporting of these genotypes in the future. 
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